Verantos introduces Inflammatory Bowel Disease Pragmatic Registry for high-quality real-world evidence

Verantos has launched the Inflammatory Bowel Disease Pragmatic Registry, using advanced AI to generate high-validity real-world evidence (RWE) for ulcerative colitis and Crohn’s disease.

The goal of Verantos’ Inflammatory Bowel Disease Pragmatic Registry is to facilitate the creation of high-validity RWE for Crohn’s disease and ulcerative colitis. The registry, developed using advanced artificial intelligence, offers a comprehensive dataset with over 3 billion data points on patient care in the real world, catering to the needs of life science organizations.

According to Anand Shroff, President of Verantos,

“Pragmatic registries are made possible due to the artificial intelligence and data curation capabilities of the Verantos Evidence Platform and the Verantos Research Network. The Inflammatory Bowel Disease Pragmatic Registry empowers biopharma researchers to accelerate advanced therapies for millions of patients suffering from inflammatory bowel disease.”

The Inflammatory Bowel Disease Pragmatic Registry provides detailed insights into various aspects of patient care by leveraging both structured and unstructured data from electronic health records, along with linkage to claims and mortality data. These insights cover areas such as disease severity, treatment effectiveness, symptom management, resource utilization, and clinical outcomes.

One significant feature of the registry is its ability to segment patient populations based on demographics, exposures, and other factors. This allows life science organizations to create cohorts that closely resemble those found in clinical trials or indicated on therapy labels. This level of granularity is crucial, especially when therapeutic labels specify conditions such as, ‘moderate to severe ulcerative colitis’ rather than just ‘inflammatory bowel disease.’

The registry encompasses a wide range of variables beyond what is typically available from structured data sources. This includes symptoms, extraintestinal manifestations, disease activity, biomarkers, and findings from endoscopies. Verantos ensures the accuracy of these variables, claiming the highest level of accuracy in the industry. Additionally, the registry’s flexibility allows for the introduction of new variables, a feature unique to pragmatic approaches.

Verantos CEO Dan Riskin stated,

“The Inflammatory Bowel Disease Pragmatic Registry is a critical step forward in our understanding of real-world treatment of ulcerative colitis and Crohn’s disease. High-validity RWE programs enable more rapid and efficient evidence generation for life science companies and more tailored treatment by clinicians.”

The Inflammatory Bowel Disease Pragmatic Registry is already in use by leading biopharma companies, offering them access to rich and reliable data to support their research and development efforts. Verantos also offers pragmatic registries covering various therapeutic areas, including cardiometabolic, immunology and inflammation, neuroscience, and respiratory diseases.